Corcept Therapeutics Incorporated $CORT Shares Sold by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System decreased its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 68.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,819 shares of the biotechnology company’s stock after selling 12,645 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Corcept Therapeutics were worth $671,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. BlackRock Inc. bought a new stake in Corcept Therapeutics in the 2nd quarter valued at about $1,080,964,000. Parallel Advisors LLC increased its holdings in shares of Corcept Therapeutics by 2.5% during the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock worth $160,329,000 after purchasing an additional 96,763 shares during the period. First Trust Advisors LP raised its position in shares of Corcept Therapeutics by 213.5% in the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after buying an additional 1,480,059 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $49,185,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Corcept Therapeutics by 2.5% in the first quarter. Principal Financial Group Inc. now owns 455,248 shares of the biotechnology company’s stock valued at $18,351,000 after buying an additional 11,156 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Activity

In other Corcept Therapeutics news, insider Sean Maduck sold 13,159 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $82.25, for a total transaction of $1,082,327.75. Following the completion of the sale, the insider directly owned 9,938 shares in the company, valued at $817,400.50. This represents a 56.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel Swisher, Jr. sold 1,500 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $74.07, for a total value of $111,105.00. Following the completion of the sale, the director directly owned 1,100 shares in the company, valued at approximately $81,477. This represents a 57.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 259,435 shares of company stock valued at $28,492,179. Corporate insiders own 20.70% of the company’s stock.

Corcept Therapeutics Trading Down 4.1%

Shares of NASDAQ:CORT opened at $64.98 on Friday. The firm has a 50 day moving average of $100.01 and a 200-day moving average of $76.94. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $126.38. The stock has a market capitalization of $7.11 billion, a PE ratio of 53.38 and a beta of 0.54.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.17. The business had revenue of $340.47 million for the quarter, compared to analyst estimates of $339.12 million. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The firm’s revenue for the quarter was up 64.0% on a year-over-year basis. During the same quarter last year, the business posted $0.16 EPS. On average, research analysts predict that Corcept Therapeutics Incorporated will post 1.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CORT. HC Wainwright reissued a “buy” rating and set a $165.00 price target on shares of Corcept Therapeutics in a research report on Friday, September 18th. Zacks Research downgraded Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a research report on Monday, July 27th. Piper Sandler reissued an “overweight” rating and set a $173.00 target price (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday, November 4th. Finally, Canaccord Genuity Group raised their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $139.50.

Check Out Our Latest Research Report on CORT

About Corcept Therapeutics

(Free Report)

Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.

Featured Stories

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.